Custom Antibody Global Market Report 2025

A custom antibody is a laboratory-engineered antibody specifically developed to target a particular antigen of interest. These antibodies are designed for research, diagnostic, or therapeutic purposes, catering to the unique requirements of scientists and healthcare professionals. Custom antibodies play a crucial role in biomedical research, diagnostics, and drug development, enabling precise detection and targeting of biomolecules.

The primary types of custom antibodies include monoclonal antibodies, polyclonal antibodies, recombinant antibodies, and other variants. Monoclonal antibodies are lab-created molecules that precisely target a specific antigen, mimicking the immune system's natural pathogen-fighting mechanism. Services in this market encompass antibody development, production and purification, as well as fragmentation and labeling. The sources of custom antibodies include mice, rabbits, and other organisms. These antibodies are utilized in various fields such as oncology, infectious diseases, neurology, stem cell research, immunology, and cardiovascular diseases. The key end users of custom antibodies include pharmaceutical and biotechnology companies, academic and research institutions, contract research organizations, and hospitals and clinics.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The custom antibody market research report is one of a series of new reports from The Business Research Company that provides custom antibody market statistics, including the custom antibody industry global market size, regional shares, competitors with the custom antibody market share, detailed custom antibody market segments, market trends, and opportunities, and any further data you may need to thrive in the custom antibody industry. This custom antibody market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The custom antibody market size has grown rapidly in recent years. It will grow from $0.42 billion in 2024 to $0.47 billion in 2025 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to rising demand for custom antibodies, growing use of precision medicine, increasing prevalence of chronic diseases and cancer, increase in the number of research and development activities, and growing number of clinical trials.

The custom antibody market size is expected to see rapid growth in the next few years. It will grow to $0.76 billion in 2029 at a compound annual growth rate (CAGR) of 12.8%. The growth in the forecast period can be attributed to rising adoption of targeted immunotherapy, growing investment in biopharmaceuticals, increasing prevalence of neurodegenerative diseases, increasing demand for in vitro diagnostics (IVD) applications, and increasing healthcare expenditures. Major trends in the forecast period include personalized medicine, technological advancements in antibody engineering, advancements in biotechnology and genetic engineering, expanding therapeutic applications, and technological advancements in the purification of antibodies.

The forecast of 12.8% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. research institutions by increasing the cost of custom monoclonal antibody development services outsourced to China and South Korea, thereby delaying biomedical discoveries and elevating life science research costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing demand for personalized medicine is anticipated to drive the expansion of the custom antibody market in the coming years. Personalized medicine is a medical approach that tailors treatment and prevention strategies based on an individual's genetic makeup, lifestyle, and environmental factors. The rising demand for personalized medicine is fueled by advancements in genomics, the growing availability of biomarker-based therapies, and a heightened consumer preference for customized treatment options that enhance efficacy while minimizing adverse effects. Custom antibodies support personalized medicine by providing highly specific immune reagents that improve disease detection, therapeutic targeting, and biomarker identification for individualized treatment strategies. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients, up from six in 2022. As a result, the increasing demand for personalized medicine is driving the growth of the custom antibody market.

Leading companies in the custom antibody market are increasingly integrating advanced technologies such as artificial intelligence to enhance antibody discovery, improve specificity, and accelerate development processes. Artificial intelligence aids custom antibody development by refining antigen selection, predicting antibody-antigen interactions, and streamlining candidate screening using machine learning, ultimately leading to faster and more cost-effective biopharmaceutical research. For instance, in October 2024, Archon Biosciences Inc., a US-based biotechnology company, launched with $20 million in funding to develop computationally designed antibody cages that enable the customization of existing antibodies for therapeutic applications. Archon's proprietary technology assembles antibodies into cage structures, allowing modifications to their properties without altering their core structures. This innovation is designed to enhance antibody affinity for therapeutic targets while reducing off-target interactions, improving both efficacy and safety.

In September 2024, Leinco Technologies Inc., a US-based biotechnology company, acquired QED Biosciences Inc. for an undisclosed amount. This acquisition is intended to support Leinco Technologies' strategic growth by expanding its market presence and strengthening its offerings in the life sciences and IVD raw material sectors. QED Bioscience Inc., also a US-based biotechnology company, specializes in the design and production of custom antibodies.

Major players in the custom antibody market are Merck & Co. Inc., AbbVie Inc., Thermo Fisher Scientific Inc., Agilent Technologies Inc., Lonza Group AG, Bio-Rad Laboratories Inc., Bio-Techne Corporation, GenScript Biotech Corporation, BioLegend Inc., Abcam plc, Cusabio Biotech Co. Ltd., OriGene Technologies Inc., Cell Signaling Technology Inc., Abgent Inc., ProSci Incorporated, Santa Cruz Biotechnology Inc., Rockland Immunochemicals Inc., Creative Biolabs Inc., Novus Biologicals LLC, Creative Diagnostics Inc., Biorbyt Ltd., BIOTEM SAS, Capra Biosciences Inc., Pacific Immunology Inc., ProteoGenix SAS.

North America was the largest region in the custom antibody market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in custom antibody report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the custom antibody market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The custom antibody market consists of revenues earned by entities by providing services such as antibody production, antibody purification, and conjugation. The market value includes the value of related goods sold by the service provider or included within the service offering. The custom antibody market also consists of sales of products including antibody fragments, conjugated antibodies, and secondary antibodies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Custom Antibody Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on custom antibody market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for custom antibody ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The custom antibody market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Monoclonal Antibodies; Polyclonal Antibodies; Recombinant Antibodies; Other Types
• 2) By Service: Antibody Development; Antibody Production And Purification; Antibody Fragmentation And Labeling
• 3) By Source: Mice; Rabbit; Other Sources
• 4) By Application: Oncology; Infectious Diseases; Neurology; Stem Cells; Immunology; Cardiovascular Diseases; Other Applications
• 5) By End-User: Pharmaceutical And Biotechnology Companies; Academic And Research Institutes; Contract Research Organization; Hospitals And Clinics
• Subsegments:
• 1) By Monoclonal Antibodies: Murine Monoclonal Antibodies; Chimeric Monoclonal Antibodies; Humanized Monoclonal Antibodies; Fully Human Monoclonal Antibodies
• 2) By Polyclonal Antibodies: Rabbit Polyclonal Antibodies; Goat Polyclonal Antibodies; Sheep Polyclonal Antibodies; Other Animal-Derived Polyclonal Antibodies
• 3) By Recombinant Antibodies: Single-Chain Variable Fragment (scFv); Nanobodies; Bispecific Antibodies; Antibody Fragments
• 4) By Other Types: Aptamers; Nanobodies (Camelid Antibodies); Hybridomas
• Companies Mentioned: Merck & Co. Inc.; AbbVie Inc.; Thermo Fisher Scientific Inc.; Agilent Technologies Inc.; Lonza Group AG; Bio-Rad Laboratories Inc.; Bio-Techne Corporation; GenScript Biotech Corporation; BioLegend Inc.; Abcam plc; Cusabio Biotech Co. Ltd.; OriGene Technologies Inc.; Cell Signaling Technology Inc.; Abgent Inc.; ProSci Incorporated; Santa Cruz Biotechnology Inc.; Rockland Immunochemicals Inc.; Creative Biolabs Inc.; Novus Biologicals LLC; Creative Diagnostics Inc.; Biorbyt Ltd.; BIOTEM SAS; Capra Biosciences Inc.; Pacific Immunology Inc.; ProteoGenix SAS
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.